Key result
Trastuzumab treatment is linked to arrhythmogenic effects and electrophysiological side effects, necessitating further research to devise cardioprotective strategies.
Why the study?
Although trastuzumab-induced cardiac contractile dysfunction is extensively studied, its electrophysiological side effects remain poorly characterized despite growing evidence linking treatment with arrhythmias.
What are the mechanistic insights into the arrhythmogenic effects of trastuzumab in patients with HER2-positive malignancies?
What are the mechanistic insights into the arrhythmogenic effects of trastuzumab in patients with HER2-positive malignancies?
This review highlights the emerging evidence of trastuzumab-induced arrhythmias, emphasizing the need for further research to understand its electrophysiological side effects and develop cardioprotective strategies.
Trastuzumab cardiotoxicity limits HER2 therapy use; review leaves open optimal prevention and monitoring strategies.
Cardiovascular diseases and cancers are the leading causes of deaths globally, and an increasing proportion of cancer patients is suffering from cardiac adverse effects of chemotherapeutic drugs. Trastuzumab, a monoclonal antibody that inhibits the activity of the human epidermal growth factor receptor 2 (HER2), is a potent targeted therapy for HER2-positive malignancies. Despite the impressive antineoplastic efficacy, the cardiotoxicity of trastuzumab frequently limits its use. Trastuzumab-induced cardiac contractile dysfunction has been extensively studied, yet the electrophysiological side effect of trastuzumab remains poorly characterized. Growing evidence from basic and clinical studies supports the link between trastuzumab treatment and arrhythmias. This review comprehensively summarizes relevant information from those reports, discusses their limitations, and suggests future research directions. We aim to encourage further investigations that will provide valuable insights to devise cardioprotective strategies against trastuzumab-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Siri‐Angkul et al. (2021) conducted a review in HER2-positive malignancies and trastuzumab-induced arrhythmias. Trastuzumab was evaluated. Trastuzumab treatment is linked to arrhythmogenic effects and electrophysiological side effects, necessitating further research to devise cardioprotective strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: